Metformin: Up to Date.
CONCLUSION: Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost.
PMID: 31670618 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Heart | Heart Failure | Insulin | Metformin | Polycystic Ovary Syndrome | Pregnancy